• Approved

• Grant

• Independent Investigators

• SAM
• GRANTS
• eBRAP

The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Early Investigator Research Award (EIRA) supports Multiple Sclerosis-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. All applications must address at least one of the FY26 MSRP EIRA focus areas.

The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies.

Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level:

• Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, or other clinical trials that are appropriate for this funding level. Preliminary data relevant to the proposed clinical trial are required.
• Funding Level 2 (CTA-FL2) supports larger-scale clinical trials at phase 1 or phase 2 that seek to show preliminary evidence of safety or efficacy (i.e., benefit of clinical or paraclinical outcomes) in relevant patient populations. Clear description and justification should be provided, which could include, but is not limited to, the intervention type, trial duration, sample size, outcome measures, assessment tools and frequency of assessment. Preliminary data relevant to the proposed clinical trial in MS populations are required.

The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Exploration – Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the Multiple Sclerosis (MS) research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. All applications must address at least one of the FY26 MSRP EHDA focus areas. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is not required.

The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Multiple Sclerosis (MS) research, patient care, and/or quality of life. All applications must address at least one of the FY26 MSRP IIRA focus areas. Research projects may focus on any phase of research, excluding clinical trials. The rationale for a research idea may be derived from laboratory discovery, clinical trial results, population-based studies, a clinician’s firsthand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to MS and the proposed research project.